dup-721 has been researched along with Sepsis* in 1 studies
1 review(s) available for dup-721 and Sepsis
Article | Year |
---|---|
New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.
Oxazolidinones comprise an important class of antibacterial protein synthesis inhibitors. Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse effects in therapy with the sole approved drug of this class, linezolid. This annotation describes a novel oxazolidinone agent, (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one (MRX-I), distinguished by its high activity against Gram-positive pathogens coupled with markedly reduced potential for myelosuppression and MAOI. The medical need, medicinal chemistry rationale, preclinical data, and phase I clinical trial summary for this new agent are reviewed herein. Topics: Acetamides; Animals; Anti-Bacterial Agents; Bone Marrow Cells; Clinical Trials, Phase I as Topic; Drug Design; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Linezolid; Monoamine Oxidase Inhibitors; Oxazolidinones; Pyridones; Sepsis | 2014 |